FIGURE 5.

IL-1β inflammasome effector cytokine production in LPS-primed and monomeric or aggregated α-synuclein–stimulated PBMCs of PD and HC subjects. PBMCs of 15 Parkinson disease (PD) patients and 15 healthy controls (HC) were stimulated as follows: unstimulated, LPS-stimulated, monomeric α-synuclein–stimulated, aggregated α-synuclein–stimulated, LPS-primed and monomeric α-synuclein–stimulated, or LPS-primed and aggregated α-synuclein–stimulated. IL-1β was quantified in supernatants by enzyme-linked immunosorbent assay. Summary results are shown in the bar graphs. The boxes stretch from the 25th to the 75th percentile; the line across the boxes indicates the median values; the lines stretching from the boxes indicate extreme values.